BlossomHill Therapeutics, Inc.
No SEC Form 4 filings for $BLSM in the last 30 days.
See all $BLSM insider activity →Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
BlossomHill Therapeutics (BLSM) presented Phase 1/2 trial data showing its drug BH-30643 achieved a 45% response rate in EGFR C797S-positive NSCLC patients. The stock rose 6% following the announcement. The drug has FDA Fast Track designation, and experts note its potential for addressing treatment-resistant mutations.
BlossomHill Therapeutics (BLSM) stock rose 4.4% in pre-market trading after presenting positive Phase 1/2 trial data for BH-30643 at a lung cancer conference. The drug showed a 45% response rate in treatment-resistant patients. CEO J. Jean Cui also presented at an investment conference, and Guggenheim initiated coverage with a Buy rating and $30 price target. The stock is near its 52-week high of $23.37.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BLSM (BlossomHill Therapeutics, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent BLSM coverage spans market movers, technology and insider activity.
Positive early‑stage trial data could drive further upside as the drug advances.
Positive early‑stage data may boost near‑term demand and support upside momentum.
The trial showed a 45% objective response rate and 88% disease control in EGFR C797S‑positive NSCLC patients.
Positive early data could boost the stock and spark interest in the EGFR‑mutant lung cancer market.
Fast Track status signals regulatory support and could accelerate development.
AlphAI scores every news story that mentions BLSM with an AI model for sentiment and relevance, and aggregates insider trades from BlossomHill Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.
3 min readBlossomHill Therapeutics (BLSM) presented Phase 1/2 trial data showing its drug BH-30643 achieved a 45% response rate in EGFR C797S-positive NSCLC patients. The stock rose 6% following the announcement. The drug has FDA Fast Track designation, and experts note its potential for addressing treatment-resistant mutations.
2 min readBlossomHill Therapeutics (BLSM) stock rose 4.4% in pre-market trading after presenting positive Phase 1/2 trial data for BH-30643 at a lung cancer conference. The drug showed a 45% response rate in treatment-resistant patients. CEO J. Jean Cui also presented at an investment conference, and Guggenheim initiated coverage with a Buy rating and $30 price target. The stock is near its 52-week high of $23.37.
2 min readBlossomHill Therapeutics (BLSM) will present updated Phase 1/2 SOLARA trial data on BH-30643, an investigational EGFR inhibitor, for EGFR-mutant NSCLC with C797S resistance at the 2026 World Conference on Lung Cancer. The FDA granted Fast Track designation to BH-30643 for this indication. The stock rose 4.22% to $21.74 on Monday and is up 6.62% in pre-market trading.
2 min readSeveral biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
2 min readNeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
4 min readBlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.
4 min readGORDON CARL L purchased 625,000 indirectly-held shares of BlossomHill Therapeutics, Inc. (BLSM) at $16.00 ($10.00M total) on 2026-08-10.
2 min readORBIMED ADVISORS LLC purchased 625,000 indirectly-held shares of BlossomHill Therapeutics, Inc. (BLSM) at $16.00 ($10.00M total) on 2026-08-10.
2 min readSchmid John P. purchased 6,000 shares of BlossomHill Therapeutics, Inc. (BLSM) at $16.00 on 2026-08-10.
1 min read
